



Published in final edited form as:

Andrology. 2019 November ; 7(6): 867–877. doi:10.1111/andr.12625.

Semen quality is affected by *HLA* class I alleles together with sexually transmitted diseases

Patrícia Isabel Marques^{1,2}, Joana Catarina Gonçalves^{1,2}, Catarina Monteiro^{1,2}, Bruno Cavadas^{1,2,3}, Liina Nagiraja⁴, Nuno Barros⁵, Alberto Barros^{1,5,6}, Filipa Carvalho^{1,6}, Alexandra M. Lopes^{1,2}, Susana Seixas^{1,2}

¹Instituto de Investigação e Inovação em Saúde, Universidade do Porto (i3S), 4200-135 Porto, Portugal

²Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), 4200-135 Porto, Portugal

³Abel Salazar Institute of Biomedical Sciences (ICBAS), University of Porto, 4050-313 Porto, Portugal

⁴Department of Genetics, Washington University School of Medicine, St. Louis, Missouri 63108, USA

⁵Center for Reproductive Genetics Alberto Barros, 4100-009 Porto, Portugal

⁶Genetics, Department of Pathology, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal.

Abstract

Background: The *human leukocyte antigen (HLA)* locus includes several genes with key roles in antigen presentation and immune response, some of them inclusively found to be associated with non-obstructive azoospermia. Still, *HLA* connections to other infertility phenotypes such as semen hyperviscosity (SHV), asthenozoospermia (AST) and oligozoospermia (OLI) have been often neglected.

Objectives: In this work, we aimed to evaluate the association of *HLA* class I and II genes with SHV, AST and OLI phenotypes while exploring a possible role in an adaptive immune response to sexually transmitted diseases (STD).

Materials and methods: Whole exome sequencing was performed in a Portuguese cohort of 71 infertility cases and 68 controls, followed by *HLA* typing using a specific software - HLA*PRG:LA tool. Molecular screenings of seven STD were carried out in a subset of 72 samples (30 cases and 42 controls).

Results: Statistical tests uncovered three protective alleles: *HLA-A*11:01*, associated with all forms of male infertility ($P=0.0006$); *HLA-DQB1*03:02* with SHV and OLI ($P_{SHV}=0.0303$, $P_{OLI}=0.0153$) and *HLA-A*29:02* with OLI ($P=0.0355$), which was found to interfere in sperm

number together with HPV ($P=0.0313$). Five risk alleles were also identified: two linked with SHV (*HLA-B*50:01*, $P=0.0278$; and *HLA-C*06:02*, $P=0.0461$), another one with both SHV and OLI (*HLA-DQA1*05:01*, $P_{SHV}=0.0444$ and $P_{OLI}=0.0265$) and two with OLI (*HLA-C*03:03*, $P=0.0480$; and *HLA-DQB1*03:01*, $P=0.0499$). Here, *HLA-C*03:03* carriers tend to be HPV infected.

Conclusions: The application of HLA*PRG:LA tool to the study of male infertility, provided novel insights for an *HLA* correlation with semen quality, namely among SHV and OLI phenotypes. The discovery of an *HLA-A*29:02*/HPV crosstalk, together with former reports of *HLA* alleles conferring resistance-susceptibility to diverse human pathogens raises the hypothesis of a mechanistic link between male infertility, *HLA* polymorphism and host response to STD.

Keywords

male infertility; semen hyperviscosity; oligozoospermia; association study; HLA-A; HPV

INTRODUCTION

Infertility is a major health issue that affects 10–20% of couples within reproductive age and in which male factors, either alone or in combination with female causes, are known to contribute to its etiology in ~50% of cases¹. More specifically, male infertility is a multifactorial disorder with a large phenotypic variability in semen quality, including: azoospermia (AZO) and oligozoospermia (OLI), for spermatozoa absence or low counts, respectively; asthenozoospermia (AST), for reduced spermatozoa motility; and semen hyperviscosity (SHV), for the persistence of semen viscous properties after its expected liquefaction time². Although such abnormalities may in some instances be correlated with congenital defects, endocrine dysfunction, urogenital infections and genetic anomalies, in a high proportion of cases the underlying causes for male infertility remain unknown³.

In the last decade, several genome-wide association studies (GWAS) shed some light into the genetic makeup of this disorder, mainly concerning non-obstructive azoospermia (NOA), by uncovering novel susceptibility genes like *PDE3A* (*phosphodiesterase 3A*), *SOX5* (*SRY-box 5*), *DMRT1* (*doublesex and mab-3 related transcription factor 1*) and *HLA-DRA* (*major histocompatibility complex, class II, DR alpha*)^{4–6}. Aside from these GWAS, some candidate gene approaches centered on *HLA* classes I and II also reported several associations with specific *HLA* alleles (*HLA-A*26*, *HLA-A*28*, *HLA-A*33*, *HLA-B*18*, *HLA-B*44*, *HLA-DPB1*04:01*, *HLA-DQB1*06:04* and *HLA-DRB1*13:02*) and idiopathic male infertility^{7–10}. However, once again these studies were predominantly focused on NOA patients and in most instances in men of East Asian ancestry.

In overview, the *human leukocyte antigen* (*HLA*) locus (6p21.32–22.1) is one of the most peculiar regions of our genome, characterized by high levels of polymorphism and heterozygosity, as well as extended linkage disequilibrium (LD) across different alleles. Briefly, the *HLA* system contains several genes and pseudogenes that can be divided into class I, II and III^{11,12} (Supplementary Fig. S1A). Even though all three classes are involved in the immune response, *HLA* class I and II molecules are the ones in charge of antigen presentation to T cells. Classical *HLA* class I genes, *HLA-A*, *-B*, and *-C*, are expressed in

most cells, where they code for distinct α -chains of HLA class I heterodimers and where the β -chain is encoded by *β 2-microglobulin* (*B2M*; 15q21.1; Supplementary Fig. S1B). On the other hand, classical *HLA* class II genes are expressed on specific immune cells, such as B cells, activated T cells, macrophages and dendritic cells, and are organized in three families: *HLA-DP*, *-DQ* and *-DR*. Each family comprises at least two genes coding for α - and β -chain molecules (Supplementary Fig. S1). Here, *HLA-DR* family accommodates a copy number variation (CNV), determining the origin of β -chains in *HLA-DRB3*, *-DRB4* or *-DRB5* genes (Supplementary Fig. S1C)¹³.

Importantly, several alleles of *HLA* class I and II genes have already been correlated with sexually transmitted disease (STD) caused by *Neisseria gonorrhoeae* (gonorrhea)^{14,15}, *Chlamydia trachomatis*^{14,16}, *Treponema pallidum* (syphilis)^{17,18}, human immunodeficiency virus (HIV)^{19,20}, human papilloma virus (HPV)²¹, hepatitis B virus (HBV)²² and hepatitis C virus (HCV)^{23–25}. Such microbial agents *per se* and together with activated immunological processes can lead to anatomical obstruction, compromise normal gland function, affect the availability of diverse seminal components and interfere in spermatozoa viability^{26–30}. To be more precise, HIV, HPV and HBV, can be internalized by spermatozoa causing DNA damage and altering sperm number, motility and morphology, while in case of HBV, it can also induce the production of antisperm antibodies (ASA)^{29,31–37}. Likewise, *C. trachomatis* and *N. gonorrhoeae* infections, as well as other bacteriospermias in general, may reduce semen quality by multiple mechanisms such as genital tract dysfunction, impaired spermatogenesis and bacterial cellular interactions^{38–42}.

In this work, we investigated the association of *HLA* class I and II genes to SHV, AST (two less explored infertility phenotypes) and OLI, by applying for the first time the *HLA*PRG:LA* tool⁴³ to a whole exome sequencing (WES) panel generated in a Portuguese cohort of patients and controls. The algorithm implemented through *HLA*PRG:LA* tool has the advantage over standard alignment methods used for the analysis of next-generation sequencing data, since it compares collected reads against multiple available *HLA* sequences instead of a single human reference. Thus, this method allows to circumvent the mapping problems arising from high polymorphism levels and from the presence of multiple paralog genes within the *HLA* locus. Then, for those *HLA* alleles showing significant associations with male infertility, we screened seven well known pathogens to test the hypothesis of increased susceptibility/resistance to STD.

Overall, our results provide further evidence for a possible association of *HLA* locus variability with male infertility, which we propose to be connected with an adaptive immune response to sexually transmitted pathogens often underlying asymptomatic urogenital infections or on the other hand, with an autoimmune reaction leading to the production of anti-sperm antibodies.

MATERIAL AND METHODS

Ethical approval

This study has been conducted in accordance with the ethical standards of the involved institutions and with the Helsinki Declaration. All participants provided written informed consent.

Patient recruitment and classification

A total of 139 samples were selected from a previous cohort of Portuguese men undergoing spermogram analysis, for which peripheral blood and semen were collected^{44,45}. Since our infertility patients (N=71; mean age=37.3±4.33) showed several abnormal parameters in spermogram, samples were stratified into three non-mutually exclusive phenotypes: SHV (semen drops form a thread >2cm long; N=61), AST (rapid progressive motility <25%; N=45) and OLI (sperm counts <20million/mL; N=28)². Samples that did not fit any of these infertility criteria were considered as controls (N=68; mean age=36.6±4.29). This cohort was excluded for male accessory gland infections (negative results in seminal culture), four sexually transmitted virus (HIV; HBV; HCV; and human T lymphotropic virus - HTLV) and syphilis (*T. pallidum*)^{44,45}. Individuals with known infertility causes, including chromosome anomalies and Yq microdeletions, were not considered in this study.

Whole exome sequencing (WES)

DNA was extracted from peripheral blood leukocytes using Citogene Blood Kit (Citomed). For cases, exonic and UTR regions were captured by SureSelect Human All Exon V5+UTR enrichment kit and paired-end sequenced on an Illumina HiSeq 2000 (Macrogen Inc, Seoul, South Korea). Raw reads were mapped to the human reference genome (GRCh37) using BWA-MEM v.0.7.15 with default parameters⁴⁶. Picard v.1.138 (<http://broadinstitute.github.io/picard/>) and Samtools v.1.2⁴⁷ were applied for post-alignment processes such as indexing, sorting and marking duplicates. The alignments were further submitted to indel realignment and base quality score recalibration using the Genome Analysis Toolkit (GATK) v. 3.4-0-g7e26428⁴⁸.

Control samples were analyzed in the framework of the Genetics of Male Infertility Initiative (GEMINI; <http://gemini.wustl.edu/>), aiming to map the genetic architecture of severe male fertility. Up to 39.1 Mb of exonic regions were captured using in-house exome targeting reagent and submitted to paired-end sequencing on Illumina HiSeq 4000 at the McDonnell Genome Institute of Washington University (genome.wustl.edu). The mapping and alignment procedures were similar to the approach applied to cases. In summary, raw reads were processed with Picard v.2.10.0 and samtools v.1.6 and mapped to the human reference genome assembly GRCh38 in an alternate contig-aware manner using BWA-MEM v.0.7.17 followed by INDEL recalibration and base quality score recalibration using GATK v.3.6.0. These WES data were extracted from two larger and ongoing works yet to be published.

HLA type inference

HLA typing using WES data was performed with HLA*PRG:LA program^{43,49}, a bioinformatics tool published only on bioRxiv (not peer-reviewed). This tool has the advantage of automatically detecting the genome version of inputted BAM files and using a population reference graph (PRG) framework to impute HLA alleles for 10 genes (*HLA-A*, *-B*, *-C*, *-DQA1*, *-DQB1*, *-DPA1*, *-DPB1*, *-DRB1*, *-DRB3* and *-DRB4*). Two caveats of HLA*PRG:LA is that the model does not take into account the number of copies of *HLA-DRB* paralogs nor analyzes *HLA-DRB5*. Hence, we followed HLA*PRG:LA method recommendations and used the obtained coverage of *HLA-DRB3* and *-DRB4* together with *HLA-DRB1* alleles to infer the CNV: *HLA-DRB3*, *-DRB4*, or *-DRB5*^{13,43}. Moreover, the presence/absence of *HLA-DRB5* was confirmed in all individuals by two amplicons. Positive samples were sequenced with BigDye Terminator v3.1 Cycle Sequencing Kit on an ABI 3130 automated sequencer. PCR conditions for *HLA-DRB5* are described in Supplementary Table S1.

Molecular screening of sexually transmitted diseases (STD)

A subset of 72 samples (42 controls and 30 cases, distributed by phenotypes as 29 SHV, 20 AST, 16 OLI) was evaluated for seven well-known agents of STD: *C. trachomatis*, *N. gonorrhoeae*, *Ureaplasma urealyticum*, *Mycoplasma genitalium*, herpes simplex virus –1 and –2 (HSV-1; HSV-2) and HPV. To this end, total DNA was extracted from seminal plasma using QIAamp DNA mini kit (Qiagen) and several duplex and multiplex PCR reactions were carried out using primers reported in the literature^{50–53} (for PCR conditions see Supplementary Table S2). All samples were amplified in triplicate and all PCR reactions were performed in the presence of negative and positive controls for each one of the tested STD. To confirm PCR specificity, obtained amplicons were submitted to Sanger sequencing (BigDye Terminator v3.1 Cycle Sequencing Kit on an ABI 3130 automated sequencer) and inspected using BLAST tool and NCBI database (<https://www.ncbi.nlm.nih.gov/>).

Statistical analysis

To consider all possible associations to male infertility, four sets of comparisons were carried out in this study – all cases, SHV, AST or OLI.

Hardy–Weinberg equilibrium (HWE)—The HWE was evaluated at gene-level for controls and cases, separately, using PyPop v0.7.0⁵⁴ and assuming Guo and Thompson's test⁵⁵. Then, Chen's measure was used to identify those genotypes explaining the observed departures from HWE⁵⁶.

Association tests for HLA alleles—Identified HLA alleles (4-digit resolution, corresponding the first 2-digits to the allele group and the remaining ones to specific HLA proteins) were divided into common or rare according to their frequency (f) in the control sample ($f \geq 0.01$ and $f < 0.01$, respectively). For common alleles, differences between cases and controls were estimated using Fisher's exact test implemented in PyHLA package⁵⁷. Next, a Bonferroni correction was used to adjust P -values for multiple comparisons in which the number of observed common alleles per gene was used as the number of tests. Welch's ANOVA was also performed for those alleles showing associations with either AST or OLI

and nominal P -values < 0.05 (IBM SPSS Statistics v.25). For these tests, the entire cohort was used to evaluate the effect of *HLA* alleles on quantitative spermiogram parameters: sperm motility (fast forward progression) and sperm number, respectively. Taking into account the limited statistical power of these approaches to detect rare variant associations, an enrichment analysis of *HLA* alleles with $f < 0.01$ was assessed by a simplified CAST test^{58,59}. Essentially, the number of chromosomes carrying rare alleles was compared between cases and controls using a 2×2 contingency table and Fisher's exact test.

Haplotype analysis—To evaluate the hypothesis of a non-random association of *HLA* alleles due to local high LD levels, pairwise D' statistics were calculated using Pypop software⁵⁴. For allele pairs found to be strongly correlated ($D' > 0.85$), the corresponding haplotypes were inferred using the bigdawg R package⁶⁰, and their association to different infertility phenotypes was addressed by Fisher's exact tests. Moreover, to assess if those allele pairs contribute to a phenotype in a combined manner or if one of them results from a spurious association caused by LD, we used the statistical genetic approach called "interaction analysis" from PyHLA software⁵⁷.

Amino acid sharing analysis—To circumvent a possible lack of statistical power due to a reduced sample size or because of multiple comparisons, an amino acid sharing approach was implemented in our analysis. Specifically, association tests at residue level were performed for both common and rare alleles with the bigdawg R package using only *HLA* regions known to encode antigen recognition sites (exon 2 and 3 for class I and exon 2 for class II genes)⁶⁰. Contingency tables and χ^2 tests were first performed for each polymorphic amino acid position, followed by contingency tables and Fisher's exact test for each residue with significantly associated positions. For variants with expected counts below five (cases or controls), comparisons were done in a single combined category. The results are expressed according to the mature protein numbering.

Copy number variation (CNV) association tests—In the association analysis of *HLA-DRB3*, *-DRB4* and *-DRB5*, we used two approaches. In the first one, *HLA-DRB3*, *-DRB4*, *-DRB5* or none of the previous were treated as alternative alleles of a single CNV locus (a 2×4 contingency table and χ^2 test was used). In the second approach, three bi-allelic CNV loci corresponding to the presence or absence of *HLA-DRB3*, *-DRB4* and *-DRB5* were considered (three 2×2 contingency tables and Fisher's exact test were employed). In all instances, GraphPad Prism 5 software (GraphPad Software) was used to evaluate statistical significance of association.

Association tests for STD—To evaluate the strength of STD association to male infertility, we used the data from our molecular screening to perform Fisher's exact tests (2×2 contingency tables for cases vs. controls). In addition, Welch's ANOVA was carried out for sperm number and sperm motility variables. Then, to address whether detected *HLA* associations could be related with a host response to STD, two statistical approaches were used: Fisher's exact tests were employed to compare presence/absence of *HLA* allele with STD; and two-way ANOVAs were carried out to accommodate the interaction between *HLA* allele, STD and the semen parameters "sperm number" or "sperm motility". These analyses

were performed for STD as a whole and for *C. trachomatis* and HPV separately. In all instances, IBM SPSS Statistics v.25 was used to evaluate statistical significance.

RESULTS

Fine-mapping of *HLA* alleles in male infertility

To assess a possible genetic influence of classical *HLA* class I and II genes into abnormal semen parameters, we analyzed the *HLA* allelic variation in 71 infertility cases and 68 controls genotyped as part of a whole-exome study (unpublished data). A large number of alleles were found in the full cohort: 113 common ($f \geq 0.01$) and 63 rare ($f < 0.01$) (Supplementary Table S3). Globally, no violation of HWE was observed in our control dataset for *HLA-A*, *-B*, *-C*, *-DQA1*, *-DQB1*, *-DRB1*, *-DPA1* and *-DPB1* eliciting its usage in the following disease association tests.

Among common *HLA* alleles, eight showed significant differences ($P < 0.05$) between cases and controls (Table 1 and Fig. 1). Remarkably, seven of these associations could be correlated with one or two male infertility phenotypes. For instance, *HLA-C*03:03* and *HLA-C*06:02* were both detected as risk alleles for OLI and SHV, respectively. On the other hand, in *HLA-DQB1* gene, whereas *HLA-DQB1*03:01* was identified as an OLI risk allele, *HLA-DQB1*03:02* was classified as a protective allele for OLI and SHV. The single association that appears to be transversal to male infertility (all cases) is correlated with *HLA-A*11:01* allele that is absent from patients, while presenting a 7.4% frequency in controls. Even though this was the only allele reaching statistical significance after Bonferroni correction ($P < 0.0029$), other alleles displaying nominal P -values < 0.05 were correlated as well with the quantitative variables sperm number or sperm motility (Table 2).

To overcome the low power of standard statistical methods to detect *HLA* rare allele associations, we performed an approach similar to the burden tests currently recommended for low-frequency variants with $f < 0.01$ ^{58,61}. Overall, a significant enrichment of rare alleles was identified for the entire *HLA* locus and across all four comparisons (Table 3). However, in a later gene-based analysis, the higher burden of rare alleles was found to be mainly attributed to *HLA-A* and *-B*, and SHV and/or AST phenotypes. These results also seem to explain the significant HWE departures detected for *HLA-A* in the full case set and in SHV patients ($P = 0.0418$ and $P = 0.0486$, respectively), which are probably connected with the occurrence of several unique genotypes (data not shown).

Haplotype analysis

The pairwise LD analysis performed for the eight studied *HLA* genes uncovered nine regions with unusual LD levels (Supplementary Table S4). Among these, three could be connected with previously identified signals of association to male infertility (Table 1). A first one spanning *HLA-A* and *-B* ($D'_{SHV} = 0.86$), a second comprising *HLA-B* and *-C* ($D'_{SHV} = 0.91$) and a last one encompassing *HLA-DQA1* and *-DQB1* genes ($D'_{SHV} = 0.87$; $D'_{OLI} = 0.87$). Indeed, *HLA-B*50:01* and *HLA-C*06:02* were found to co-segregate in one of the most prevalent *HLA-B~HLA-C* haplotypes in SHV cases ($f_{controls} = 0.007$ and $f_{SHV} = 0.066$; $P = 0.0118$ and OR = 9.47). A similar finding was obtained for *HLA-DQA1*05:01*

and *HLA-DQB1*03:01* alleles in the most common OLI haplotype ($f_{\text{controls}} = 0.125$ and $f_{\text{OLI}} = 0.250$; $P = 0.0298$ and $OR = 2.33$). On the other hand, the associations of *HLA-A*11:01* and *HLA-DQB1*03:02* (Table 1) to infertility phenotypes appear to be independent and not a by-product of the high LD levels observed for *HLA-A~HLA-B* and *HLA-DQA1~HLA-DQB1* (Supplementary Table S4), given that neither of these alleles were linked to other significantly associated alleles.

In order to assess if co-segregating *HLA* alleles were both playing a role in SHV and OLI, or if one of them was a spurious association caused by LD, we tested the hypothesis of a combined allele contribution to the disease. According to our results, in both instances, the two alleles are likely to confer an increased infertility risk (*HLA-B*50:01* / *HLA-C*06:02* pair $P = 0.0117$ and $OR = 7.53$; *HLA-DQA1*05:01* / *HLA-DQB1*03:01* pair $P = 0.032$ and $OR = 3.24$).

Amino acid association analysis

To unravel functionally important domains of HLA molecules that otherwise may not emerge as associated to disease, we performed an analysis based on the amino acid variation. This approach led to similar results as the previous tests with *HLA-A*, *-B*, *-DQA1* and *-DQB1* showing associations to different infertility phenotypes (Table 1 and Supplementary Table S5). Interestingly, the protective effect of *HLA-A*11:01* and *HLA-A*29:02* to male infertility in general and to OLI, respectively, seems to be explained by the occurrence of a tyrosine (p.Y9 in *HLA-A*11:01*) or threonine (p.T9 in *HLA-A*29:02*) at residue 9 in prejudice of the phenylalanine (p.F9) (Fig. 2 and Supplementary Tables S5–S10). Concerning *HLA-B*50:01* association with SHV, it is probably correlated with the increment of p.E152 in SHV over p.V152 (Fig. 2 and Supplementary Tables S6 and S10). In addition, for *HLA-B* the myriad of associations observed in AST is likely to be connected with the aforementioned enrichment of rare alleles and to a sharing of specific amino acid residues (Table 3 and Supplementary Tables S5, S8 and S10). Regarding *HLA-DQA1*05:01*, it appears to be related with the prevalence of p.S75 in OLI cases in contrast to p.I75 in controls (Fig. 2 and Supplementary Tables S9 and S10). Finally, the *HLA-DQB1*03:01* allele conferring risk to OLI is possibly connected with p.A13, p.Y26 and p.45E in contrast to p.G13, p.L26 and p.G45 residues that are more common in controls and associated to the protective allele *HLA-DQB1*03:02* (Fig. 2 and Supplementary Tables S9 and S10).

Copy number variation of *HLA-DRB3*, *-DRB4* and *-DRB5*

We started our analysis by treating the CNV as a single locus (Table 4), which uncovered a significant result between OLI and controls ($\chi^2 = 10.4559$ and $P = 0.0151$). Then, further tests were performed for the presence or absence of each paralog in a multiple loci approach that disclosed the association of *HLA-DRB3* with SHV and OLI ($P = 0.0454$ and $P = 0.0023$, respectively) and of *HLA-DRB4* with OLI alone ($P = 0.0123$; Table 4).

STD screening in seminal plasma

To investigate whether *HLA* associations to male infertility could be related with susceptibility or resistance to STD, we screened seven well-known pathogens in a subset of

30 cases and 42 controls. Among tested STD, only *C. trachomatis*, *N. gonorrhoeae*, *U. urealyticum* and HPV were detected in the seminal plasma either alone or as co-infections (Supplementary Table S11). The most prevalent pathogens were *C. trachomatis* and HPV, but no differences were observed between cases and controls (*C. trachomatis*: $f_{controls} = 0.429$ vs. $f_{cases} = 0.300$; HPV: $f_{controls} = 0.286$ vs. $f_{cases} = 0.400$). Still, for HPV, previous reported associations with lower sperm numbers^{29,30} were confirmed in this study when this parameter was considered as a quantitative trait (Fig. 3). No similar association was observed for *C. trachomatis* or STD in general (Fig. 3).

Next, we examined whether STD prevalence diverged between carriers and non-carriers of *HLA* alleles associated to male infertility (nominal $P < 0.05$). For *HLA-A* locus, this revealed two times less STD affected subjects in the presence of the protective allele *HLA-A*11:01* ($P = 0.1096$; OR = 0.2341; 95% CI = 0.0421–1.3017; Supplementary Fig. S2). On contrary, for *HLA-C*03:03* a two-fold increase in HPV infected individuals was connected with this risk allele ($P = 0.0906$; OR = 4.6000; 95% CI = 0.7783–27.1885; Supplementary Fig. S2). Finally, statistical models of interaction were taken into account in the analysis of *HLA* allele, STD and infertility outcome. Notably, these tests showed that *HLA-A*29:02* and HPV had an effect in sperm concentration ($P = 0.0313$), in which the highest sperm counts, even within the normal range, were observed in the presence of *HLA-A*29:02* without HPV, differing from any other combination of analyzed variables (Fig. 4).

DISCUSSION

In this work, we evaluated the possible contribution of classical *HLA* variability into the etiology of different male infertility phenotypes, SHV, AST and OLI, through the analysis of a WES panel of Portuguese patients and controls. We identified three protective (*HLA-A*11:01*, *HLA-A*29:02* and *HLA-DQB1*03:02*) and five risk alleles (*HLA-B*50:01*, *HLA-C*03:03*, *HLA-C*06:02*, *HLA-DQA1*05:01* and *HLA-DQB1*03:01*). Notably, none of these have been previously linked to male infertility, neither former described associated alleles were replicated in this study^{4,7–10,62,63}. This is not entirely unexpected given that the analyzed populations and phenotypes are quite distinct. Indeed, except for the work of Aleksovski *et al.* that analyzed men from the former Yugoslavia with impaired spermatogenesis (OLI or AZO), all the remaining studies were performed in NOA patients with East-Asian ancestry^{4,7–10,62,63}. Moreover, in many instances, *HLA* alleles linked to male infertility are found at contrasting frequencies in different human populations⁶⁴, indicating that previous findings might have been influenced by the ethnicity of analyzed samples and thus restricted to those populations. Interestingly, as pivotal players in the immune response, *HLA* molecules are thought to have been shaped by natural selection, and their polymorphism is known to correlate with geography (distance from Africa) and pathogen richness⁶⁵. In this sense, the selective pressures exerted by a higher burden of infectious agents might have favored *HLA* diversification, especially in certain continental regions, to recognize a broader repertoire of pathogenic peptides^{65–68}.

Despite the absence of a prevailing rule on how *HLA* classes access antigens, class I molecules are believed to mainly bind intracellular peptides of viral origin, triggering a cytotoxic response by their presentation to CD8+ T cells. Conversely, class II molecules are

thought to bind mostly to extracellular antigens of bacterial origin that, once presented to CD4+ T cells, stimulate antibody production by B cells^{11,66,69,70}. Therefore, HLA classes I and II would be expected to have dissimilar outcomes in STD like gonorrhea (*N. gonorrhoeae*) and syphilis (*T. pallidum*), and infections caused by *C. trachomatis*, HPV, HSV, HIV, HBV and HCV, which are all accepted risk factors for male infertility²⁹. However, according to our study results, only class I genes (*HLA-A* and *-C*) appear to influence the outcomes of HPV infection and STD in semen quality.

Notably, some of our candidate alleles for male infertility were already associated in the context of other disorders with several of these pathogens. For example, *HLA-A*11:01* and *HLA-DQB1*03:02* were both described to confer resistance against HIV and in the case of *HLA-DQB1*03:02* it was also reported to protect from HBV in chronic hepatitis^{19,20,22}. Consistently, in our cohort, *HLA-A*11:01* and *HLA-DQB1*03:02* were correlated with a lower overall risk to male infertility and to SHV and OLI, respectively. These findings are therefore suggestive of a protective role through an improved immune response against HIV and HBV, but also possibly to other viruses, given that the presence of HIV and HBV was excluded in our samples⁴⁵. Indeed, this assumption seems to apply to another class I allele, *HLA-A*29:02*, for which we found evidence of a relationship with HPV infection in sperm counts.

Concerning *HLA-DQB1*03:01* allele, identified as a risk factor for OLI, previous studies showed conflicting results: whereas in chronic hepatitis this allele has been correlated in some instances with HCV clearance^{23–25}, other authors have reported a link between *HLA-DQB1*03:01* and HPV6 infection²¹. Notably, this HPV subtype, despite being considered as low-risk for cervical cancer, is established to cause genital lesions and to be found in the semen^{71,72}. In our cohort, no association of *HLA-DQB1*03:01* with HPV was not detected. However, it is important to note that no discrimination of HPV subtypes was done in our STD screening. Given that some HPV subtypes have more severe outcomes in semen quality than others, our molecular analysis might have hampered the detection of any association signal⁷³.

Less is known about bacterial agents, but for *HLA-DQA1*05:01* allele correlated with OLI and SHV, a previous work showed contrasting results among women infected by *C. trachomatis* and *N. gonorrhoeae*. While in positive *C. trachomatis* cases *HLA-DQA1*05:01* had an increased frequency, in *N. gonorrhoeae* patients this allele displayed only reduced counts^{14,29}. However, as far as we could evaluate, no association of *HLA-DQA1*05:01* with *C. trachomatis*, nor with *N. gonorrhoeae* (found in a single case), was detected in our sample.

Noteworthy, our cohort overlaps with the one used for a global characterization of seminal microbiota, in which pooled samples of controls, asthenoteratozoospermia, oligoasthenoteratozoospermia (OAT) and SHV were screened by sequencing 16S ribosomal RNA gene⁴⁵. Again, according to Monteiro *et al.*, the above association of *HLA-DQA1*05:01* to *Chlamydia* alone seems improbable, given that its relative abundance compared to other bacterial taxa only reaches very low frequencies ($f < 0.1\%$). On contrary, *Neisseria* and other infectious agents known to cause urogenital infections, namely

Haemophilus, *Pseudomonas*, *Klebsiella*, and *Serratia*, were found to be augmented in OAT and/or SHV samples⁴⁵. Although the different methodological approaches and sample subsets used in these studies might have prevented a throughout appreciation of their findings, the complexity of seminal microbiota still suggests the existence of multiple targets for HLA antigenic presentation in the male urogenital system.

Taking into account the above considerations, it is tempting to hypothesize *HLA* alleles as critical immunological players in STD susceptibility. Supporting this conjecture is the evidence for an activation of the immune system in asymptomatic OAT patients as shown by their infiltrations of HLA-DR positive macrophages in the ejaculate and also the expression of *HLA* class II genes in spermatozoa of infertile men^{74,75}. Nevertheless, we cannot rule out an autoimmunity cause for our findings, since *HLA* alleles can be associated with ASA production and male infertility as well^{76,77}.

In conclusion, we were able to apply for the first time a population reference graph approach implemented through HLA*PRG:LA tool to the study of male infertility. This allowed us to infer *HLA* genotypes from a panel of WES data as well as to perform a preliminary study of *HLA* variability in this disease. Even though our cohort may be considered as small sized it was enough to provide novel hints for a possible role of *HLA* locus in this complex disorder. We demonstrate that both *HLA* class I and II alleles can be correlated with SHV and OLI phenotypes and that these also appear to be implicated in the susceptibility/resistance to different pathogens known to cause male urogenital infections and to affect reproductive fitness. Future studies in extended WES cohorts, followed by seminal transcriptomics research of human and pathogens will be fundamental to assess the proposed host-pathogen interaction in male infertility.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS

We want to thank all patients for donating their samples and for collaborating in this study, Don Conrad for providing access to exome sequencing under the auspices of the GEMINI consortium and Maria José Borrego (National Institute of Health, Lisbon, Portugal) for supplying DNA samples as positive controls for STD. Ipatimup integrates the i3S Consortium, which is partially supported by the Portuguese Foundation for Science and Technology (FCT). This work was supported by Norte Portugal Regional Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (FEDER) - project NORTE-01-0145-FEDER-000029. This work was also financed by FEDER funds through COMPETE 2020 (Operational Programme for Competitiveness and Internationalization - POCI) and by Portuguese funds through FCT - project POCI-01-0145-FEDER-007274, grant PTDC/BEX- GMG/0242/2012 to S.S. and fellowship SFRH/BPD/120777/2016 to P.I.M. A.M.L is funded by the Portuguese Government through the FCT research contract IF/01262/2014. L.N. was supported by grant R01HD07864 from the Eunice Shriver Kennedy National Institute of Child Health and Human Development of the United States.

BIBLIOGRAPHY

1. Agarwal A, Mulgund A, Hamada A, Chyatte MR. A unique view on male infertility around the globe. *Reprod Biol Endocrinol*. 2015;13(37).
2. WHO. WHO Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction. 4th edn. Cambridge, UK: Cambridge University Press; 1999.

3. Jungwirth A, Diemer T, Dohle G., Giwercman A, Kopa Z, Krausz C European Association of Urology Guidelines on Male Infertility: The 2012 Update. *Eur Urol.* 2012;62:324–32. [PubMed: 22591628]
4. Hu Z, Li Z, Yu J, Tong C, Lin Y, Guo X, et al. Association analysis identifies new risk loci for non-obstructive azoospermia in Chinese men. *Nat Commun.* 2014;5:3857. [PubMed: 24852083]
5. Ramasamy R, Bakircioğlu ME, Cengiz C, Karaca E, Scovell J, Jhangiani SN, et al. Whole-exome sequencing identifies novel homozygous mutation in NPAS2 in family with nonobstructive azoospermia. *Fertil Steril.* 2015;104(2):286–91. [PubMed: 25956372]
6. Aston KI. Genetic susceptibility to male infertility: News from genome-wide association studies. *Andrology.* 2014;2(3):315–21. [PubMed: 24574159]
7. Jinam TA, Nakaoka H, Hosomichi K, Mitsunaga S, Okada H, Tanaka A, et al. HLA-DPB104:01 allele is associated with non-obstructive azoospermia in Japanese patients. *Hum Genet.* 2013;132(12):1405–11. [PubMed: 23934009]
8. Miura H, Tsujimura A, Nishimura K, Kitamura M, Kondoh N, Takeyama M, et al. Susceptibility to idiopathic azoospermia in Japanese men is linked to HLA class I antigen. *J Urol.* 1998;159(6): 1939–41. [PubMed: 9598492]
9. Matsuzaka Y, Makino S, Okamoto K, Oka A, Tsujimura A, Matsumiya K, et al. Susceptibility locus for non-obstructive azoospermia is localized within the HLA-DR/DQ subregion: Primary role of DQB1*0604. *Tissue Antigens.* 2002;60:53–63. [PubMed: 12366783]
10. Aleksovski D, Todorov Z, Chilimanov Z. Possibilities of association of azoospermia and oligospermia with some HLA system antigens. *Hum Reprod.* 1988;3(1):83–4. [PubMed: 3162459]
11. Klein J, Sato A. The HLA System. *New Engl J Med Rev.* 2000;343(10):702–9.
12. Mosaad YM. Clinical Role of Human Leukocyte Antigen in Health and Disease. *Scand J Immunol.* 2015;82:283–306. [PubMed: 26099424]
13. Bergström TF, Erlandsson R, Engkvist H, Josefsson A, Erlich HA, Gyllensten U. Phylogenetic history of hominoid DRB loci and alleles inferred from intron sequences. *Immunol Rev.* 1999;167:351–65. [PubMed: 10319273]
14. Ness RB, Brunham RC, Shen C, Bass DC. Associations among Human Leukocyte Antigen (HLA) Class II DQ Variants, Bacterial Sexually Transmitted Diseases, Endometritis, and Fertility among Women with Clinical Pelvic Inflammatory Disease. *Sex Transm Dis.* 2004;31(5):301–4. [PubMed: 15107633]
15. GEISLER WM, WANG C, TANG J, WILSON CM, CROWLEY-NOWICK PA, KASLOW RA Immunogenetic Correlates of Neisseria gonorrhoeae Infection in Adolescents. *Sex Transm Dis.* 2008;35(7):656–61. [PubMed: 18496418]
16. Olson KM, Tang J, Brown L, Press CG, Geisler WM. HLA-DQB1*06 is a risk marker for chlamydia reinfection in African American women. *Genes Immun.* 2019;20:69–73. [PubMed: 29483614]
17. Zhuang Y-L, Ren G-J, Tian K-L, Li X-Y, Zhu Y-B, Liu J-L, et al. Human leukocyte antigen-C and killer cell immunoglobulin-like receptor gene polymorphisms among patients with syphilis in a Chinese Han population. *APMIS.* 2012;
18. Jiang H-W, Tian H-Q, Liu H, Li N, Zhao Y, Zhang F-R. Association of the HLA-DRB1 locus with syphilis in a Chinese population. *Int J Infect Dis.* 2011;15(5):e342–5. [PubMed: 21411354]
19. Raghavan S, Selvaraj P, Swaminathan S, Narendran G. Short communication: association of HLA-A*1101 with resistance and B*4006 with susceptibility to HIV and HIV-TB: an in silico analysis of promiscuous T cell epitopes. *AIDS Res Hum Retroviruses.* 2009;25(10):1023–8. [PubMed: 19803716]
20. Rallón N, Restrepo C, Vicario JL, del Romero J, Rodríguez C, García-Samaniego J, et al. Human leucocyte antigen (HLA)-DQB1*03:02 and HLA-A*02:01 have opposite patterns in their effects on susceptibility to HIV infection. *HIV Med.* 2017;18(8):587–94. [PubMed: 28218480]
21. Chen D, Gaborieau V, Zhao Y, Chabrier A, Wang H, Waterboer T, et al. A systematic investigation of the contribution of genetic variation within the MHC region to HPV seropositivity. *Hum Mol Genet.* 2015;24(9):2681–8. [PubMed: 25616963]

22. Nishida N, Ohashi J, Khor SS, Sugiyama M, Tsuchiura T, Sawai H, et al. Understanding of HLA-conferred susceptibility to chronic hepatitis B infection requires HLA genotyping-based association analysis. *Sci Rep.* 2016;6:24767. [PubMed: 27091392]
23. Huang J, Huang K, Xu R, Wang M, Liao Q, Xiong H, et al. The Associations of HLA-A*02:01 and DRB1*11:01 with Hepatitis C Virus Spontaneous Clearance Are Independent of IL28B in the Chinese Population. *Sci Rep.* 2016;6:31485. [PubMed: 27511600]
24. Thio C, Thomas D, Goedert J, Vlahov D, Nelson K, Hilgartner M, et al. Racial differences in HLA class II associations with hepatitis C virus outcomes. *J Infect Dis.* 2001;184:16–21. [PubMed: 11398104]
25. El-Bendary M, Neamatallah M, Esmat G, Kamel E, Elalfy H, Besheer T, et al. Associations of human leucocyte antigen class II-DQB1 alleles with hepatitis C virus infection in Egyptian population: a multicentre family-based study. *J Viral Hepat.* 2016;23:961–70. [PubMed: 27599887]
26. du Plessis SS, Gokul S, Agarwal A. Semen hyperviscosity-causes, consequences, and cures. *Front Biosci (Elite Ed).* 2013;5:224–31. [PubMed: 23276984]
27. Flint M, du Plessis S, Menkveld R. Revisiting the assessment of semen viscosity and its relationship to leucocytospermia. *Andrologia.* 2014;46:837–41. [PubMed: 24007306]
28. Weidner W, Pilatz A, Diemer T, Schuppe HC, Rusz A, Wagenlehner F. Male urogenital infections: Impact of infection and inflammation on ejaculate parameters. *World J Urol.* 2013;31:717–23. [PubMed: 23857546]
29. Gimenes F, Souza RP, Bento JC, Teixeira JJ V, Maria-Engler SS, Bonini MG, et al. Male infertility: a public health issue caused by sexually transmitted pathogens. *Nat Rev Urol.* 2014;11(12):672–87. [PubMed: 25330794]
30. Bezold G, Politch JA, Kiviat NB, Kuypers JM, Wolff H, Anderson DJ. Prevalence of sexually transmissible pathogens in semen from asymptomatic male infertility patients with and without leukocytospermia. *Fertil Steril.* 2007;87(5):1087–97. [PubMed: 17433312]
31. Garolla A, Pizzol D, Bertoldo A, Menegazzo M, Barzon L, Foresta C. Sperm viral infection and male infertility: focus on HBV, HCV, HIV, HPV, HSV, HCMV, and AAV. *J Reprod Immunol.* 2013;100:20–9. [PubMed: 23668923]
32. Lai YM, Soong YK, Lee JF, Yang FP, Huang HY, Pao CC. The effect of human papillomavirus infection on sperm cell motility. *Fertil Steril.* 1997;67(6):1152–5. [PubMed: 9176459]
33. Moretti A, Palù G, Foresta C, Pizzol D, Barzon L, Garolla A. Clinical and prognostic significance of human papillomavirus DNA in the sperm or exfoliated cells of infertile patients and subjects with risk factors. *Fertil Steril.* 2010;94(5):1723–7. [PubMed: 20056213]
34. Palù G, Zuccarello D, Pizzol D, Foresta C, Moretti A, Barzon L, et al. Human papillomavirus found in sperm head of young adult males affects the progressive motility. *Fertil Steril.* 2008;93(3):802–6. [PubMed: 19100537]
35. Ceballos A, Lenicov FR, Sabatté J, Rodrigues CR, Cabrini M, Jancic C, et al. Spermatozoa capture HIV-1 through heparan sulfate and efficiently transmit the virus to dendritic cells. *J Exp Med.* 2009;206(12):2717–33. [PubMed: 19858326]
36. Lorusso F, Palmisano M, Chironna M, Vacca M, Masciandaro P, Bassi E. Impact of chronic viral diseases on semen parameters. *Andrologia.* 2010;42:121–6. [PubMed: 20384803]
37. Kang X, Xie Q, Zhou X, Li F, Huang J, Liu D, et al. Effects of hepatitis B virus S protein exposure on sperm membrane integrity and functions. *PLoS One.* 2012;7(3):e33471.
38. Eley A, Hosseinzadeh S, Hakimi H, Geary I, Pacey AA. Apoptosis of ejaculated human sperm is induced by co-incubation with *Chlamydia trachomatis* lipopolysaccharide. *Hum Reprod.* 2005;20(9):2601–7. [PubMed: 15905291]
39. Hosseinzadeh S, Brewis IA, Eley A, Pacey AA. Co-incubation of human spermatozoa with *Chlamydia trachomatis* serovar E causes premature sperm death. *Hum Reprod.* 2001;16(2):293–9. [PubMed: 11157823]
40. Satta A, Stivala A, Garozzo A, Morello A, Perdichizzi A, Vicari E, et al. Experimental *Chlamydia trachomatis* infection causes apoptosis in human sperm. *Hum Reprod.* 2006;21(1):134–7. [PubMed: 16126752]

41. Domes T, Lo KC, Grober ED, Mullen JBM, Mazzulli T, Jarvi K. The incidence and effect of bacteriospermia and elevated seminal leukocytes on semen parameters. *Fertil Steril.* 2012;97(5): 1050–5. [PubMed: 22341372]
42. Mackern-Oberti JP, Motrich RD, Breser ML, Sánchez LR, Cuffini C, Rivero VE. Chlamydia trachomatis infection of the male genital tract: An update. *J Reprod Immunol.* 2013;100(1):37–53. [PubMed: 23870458]
43. Dilthey AT, Gourraud PA, Mentzer AJ, Cereb N, Iqbal Z, McVean G. High-Accuracy HLA Type Inference from Whole-Genome Sequencing Data Using Population Reference Graphs. *PLoS Comput Biol.* 2016;12(10):e1005151.
44. Marques PI, Fonseca F, Carvalho AS, Puente DA, Damião I, Almeida V, et al. Sequence variation at KLK and WFDC clusters and its association to semen hyperviscosity and other male infertility phenotypes. *Hum Reprod.* 2016;31(12):2881–91. [PubMed: 27827323]
45. Monteiro C, Marques PI, Cavadas B, Damião I, Almeida V, Barros N, et al. Characterization of microbiota in male infertility cases uncovers differences in seminal hyperviscosity and oligoasthenoteratozoospermia possibly correlated with increased prevalence of infectious bacteria. *Am J Reprod Immunol.* 2018;79:e12838.
46. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics.* 2009;25(14):1754–60. [PubMed: 19451168]
47. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. *Bioinformatics.* 2009;25(16):2078–9. [PubMed: 19505943]
48. Depristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nat Genet.* 2011;43(5):491–501. [PubMed: 21478889]
49. Dilthey AT, Mentzer AJ, Carapito R, Cutland C, Cereb N, Madhi SA, et al. HLA*PRG:LA - HLA typing from linearly projected graph alignments. *bioRxiv.* 2018;453555.
50. Abusarah EA, Awwad ZM, Charvalos E, Shehabi AA. Molecular detection of potential sexually transmitted pathogens in semen and urine specimens of infertile and fertile males. *Diagn Microbiol Infect Dis.* 2013;77:283–6. [PubMed: 24079950]
51. Mahony JB, Jang D, Chong S, Luinstra K, Sellors J, Tyndall M, et al. Detection of chlamydia trachomatis, neisseria gonorrhoeae, ureaplasma urealyticum, and mycoplasma genitalium in first-void urine specimens by multiplex polymerase chain reaction. *Mol Diagnosis.* 1997;2(3):161–8.
52. Gimenes F, Medina FS, De Abreu ALP, Irie MMT, Esquica IB, Malagutti N, et al. Sensitive Simultaneous Detection of Seven Sexually Transmitted Agents in Semen by Multiplex-PCR and of HPV by Single PCR. *PLoS One.* 2014;9(6):e98862.
53. De Roda Husman AM, Walboomers JMM, Van den Brule AJC, Meijer CJLM, Snijders PJF. The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. *J Gen Virol.* 1995;76:1057–62. [PubMed: 9049358]
54. Lancaster AK, Single RM, Solberg OD, Nelson MP, Thomson G. PyPop update - A software pipeline for large-scale multilocus population genomics. *Tissue Antigens.* 2007;69(SUPPL. 1): 192–7. [PubMed: 17445199]
55. Guo S, Thompson E. Performing the exact test of Hardy-Weinberg proportion for multiple alleles. *Biometrics.* 1992;48(2):361–72. [PubMed: 1637966]
56. Chen JJ, Hollenbach JA, Trachtenberg EA, Just JJ, Carrington M, Rønningen KS, et al. Hardy-Weinberg testing for HLA class II (DRB1, DQA1, DQB1, AND DPB1) loci in 26 human ethnic groups. *Tissue Antigens.* 1999;54:533–42. [PubMed: 10674966]
57. Fan Y, Song YQ. PyHLA: Tests for the association between HLA alleles and diseases. *BMC Bioinformatics.* 2017;18:90. [PubMed: 28166716]
58. Dering C, Hemmelmann C, Pugh E, Ziegler A. Statistical Analysis of Rare Sequence Variants: An Overview of Collapsing Methods. *Genet Epidemiol.* 2011;35(Suppl 1):S12–7. [PubMed: 22128052]
59. Morgenthaler S, Thilly WG. A strategy to discover genes that carry multi-allelic or mono-allelic risk for common diseases: A cohort allelic sums test (CAST). *Mutat Res.* 2007;615:28–56. [PubMed: 17101154]

60. Pappas DJ, Marin W, Hollenbach JA, Mack SJ. Bridging Immunogenomic Data Analysis Workflow Gaps (bigdawg): An Integrated Case-Control Analysis Pipeline. *Hum Immunol.* 2016;77(3):283–7. [PubMed: 26708359]
61. Kosmicki JA, Churchhouse CL, Rivas MA, Neale BM. Discovery of rare variants for complex phenotypes. *Hum Genet.* 2016;135:625–34. [PubMed: 27221085]
62. Zhao H, Xu J, Zhang H, Sun J, Sun Y, Wang Z, et al. A genome-wide association study reveals that variants within the HLA region are associated with risk for nonobstructive azoospermia. *Am J Hum Genet.* 2012;90:900–6. [PubMed: 22541561]
63. Hu Z, Xia Y, Guo X, Dai J, Li H, Hu H, et al. A genome-wide association study in Chinese men identifies three risk loci for non-obstructive azoospermia. *Nat Genet.* 2011;44(2):183–6. [PubMed: 22197933]
64. Gourraud PA, Khankhania P, Cereb N, Yang SY, Feolo M, Maiers M, et al. HLA diversity in the 1000 genomes dataset. *PLoS One.* 2014;9(7):e97282.
65. Prugnolle F, Manica A, Charpentier M, Guégan JF, Guernier V, Balloux F. Pathogen-driven selection and worldwide HLA class I diversity. *Curr Biol.* 2005;15:1022–7. [PubMed: 15936272]
66. Meyer D, Vitor VR, Bitarello BD, Débora DY, Nunes K. A genomic perspective on HLA evolution. *Immunogenetics.* 2018;70(1):5–27. [PubMed: 28687858]
67. Penman BS, Ashby B, Buckee CO, Gupta S. Pathogen selection drives nonoverlapping associations between HLA loci. *Proc Natl Acad Sci.* 2013;110(48):19645–50. [PubMed: 24225852]
68. Bitarello BD, Francisco R dos S, Meyer D. Heterogeneity of dN/dS Ratios at the Classical HLA Class I Genes over Divergence Time and Across the Allelic Phylogeny. *J Mol Evol.* 2016;82(1):38–50. [PubMed: 26573803]
69. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. *Helper T Cells and Lymphocyte Activation In: Molecular Biology of the Cell.* 4th editio New York: Garland Science; 2002.
70. Blum JS, Wearsch PA, Cresswell P. Pathways of Antigen Processing. *Annu Rev Immunol.* 2013;31:443–73. [PubMed: 23298205]
71. Lyu Z, Feng X, Li N, Zhao W, Wei L, Chen Y, et al. Human papillomavirus in semen and the risk for male infertility: A systematic review and meta-analysis. *BMC Infect Dis.* 2017;17(1):714. [PubMed: 29121862]
72. Flores-Díaz E, Sereday KA, Ferreira S, Sirak B, Sobrinho JS, Baggio ML, et al. HPV-6 Molecular Variants Association With the Development of Genital Warts in Men: The HIM Study. *J Infect Dis.* 2017;215:559–65. [PubMed: 28011919]
73. Yang Y, Jia CW, Ma YM, Zhou LY, Wang SY. Correlation between HPV sperm infection and male infertility. *Asian J Androl.* 2013;15:529–32. [PubMed: 23603919]
74. Paradisi R, Neri S, Pession A, Magrini E, Bellavia E, Ceccardi S, et al. Human leukocyte antigen II expression in sperm cells: comparison between fertile and infertile men. *Arch Androl.* 2000;45(3):203–13. [PubMed: 11111869]
75. Pelliccione F, D'Angeli A, Cinque B, Falone S, Micillo A, Francavilla F, et al. Activation of the immune system and sperm DNA fragmentation are associated with idiopathic oligoasthenoteratospermia in men with couple subfertility. *Fertil Steril.* 2011;95(8):2676–9. [PubMed: 21704215]
76. Omu AE, al-Qattan F, Ismail AA, al-Taher S, al-Busiri N. Relationship between unexplained infertility and human leukocyte antigens and expression of circulating autogeneic and allogeneic antisperm antibodies. *Clin Exp Obstet Gynecol.* 1999;26(3–4):199–202. [PubMed: 10668156]
77. Bohring C, Krause W. Immune infertility: Towards a better understanding of sperm (auto)-immunity: The value of proteomic analysis. *Hum Reprod.* 2003;18(5):915–24. [PubMed: 12721162]




Figure 1 - Risk effect analysis for *HLA* alleles in male infertility. The relative position of *HLA* genes (central diagram) is shown along with forest plots for alleles presenting significant associations with male infertility ($P < 0.05$). Each allele plot shows the Odds Ratios (OR) for four comparisons performed: Controls vs. oligozoospermia (OLI); Controls vs. asthenozoospermia (AST); Controls vs. semen hyperviscosity (SHV) and Controls vs. all cases. The dashed black line represents OR = 1. For each comparison OR values and confidence intervals are shown by a dot and a line, respectively, and where color denotes the allele effect: black – none (non-significant); blue – protective (significant); red – risk (significant).




Figure 2 -

Evaluation of amino acid composition of HLA-A, HLA-B, HLA-DQA1 and HLA-DQB1 alleles associated to male infertility ($P < 0.05$). Frequencies of the different residues encoded by *HLA* alleles showing significant results for semen hyperviscosity (SHV), asthenozoospermia (AST) or oligozoospermia (OLI). * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$.




Figure 3 - Effect of STD agents in sperm concentration. Group differences between sperm number and STD (all identified pathogens), *Chlamydia trachomatis* or human papilloma virus (HPV) presence/absence are shown.




Figure 4 - Interaction analysis of *HLA-A*29:02* allele and human papilloma virus (HPV) in sperm concentration. Mean sperm number and 95% confidence intervals are shown for four combinations according to allele presence or absence and to HPV infection status (HPV+ or HPV-). * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$.

Table 1 -Significant case-control associations for common *HLA* alleles.

Gene	Allele	Frequency				
		Controls	All cases	SHV cases	AST cases	OLI cases
<i>HLA-A</i>	11:01	0.074	0	0	<u>0</u>	0
	29:02	0.081	0.028	0.025	0.022	<u>0</u>
<i>HLA-B</i>	50:01	0.015	0.063	<u>0.074</u>	0.056	0.071
<i>HLA-C</i>	03:03	0.022	0.042	0.041	0.056	<u>0.089</u>
	06:02	0.052	0.113	<u>0.123</u>	0.067	0.089
<i>HLA-DQA1</i>	05:01	0.199	0.289	<u>0.312</u>	0.289	<u>0.357</u>
<i>HLA-DQB1</i>	03:01	0.169	0.197	0.197	0.222	<u>0.304</u>
	03:02	0.132	0.063	<u>0.049</u>	0.056	<u>0.018</u>

Significant nominal *P*-values ($P < 0.05$) for Fisher's exact test are underlined.Significant *P*-value after adjustment for multiple testing (Bonferroni correction) are shown in bold.

Table 2 -

Quantitative analysis of *HLA* alleles associated with male infertility ($P < 0.05$).

Gene	Allele	Welch's ANOVA <i>P</i> -value	
		Sperm number	Sperm motility
<i>HLA-A</i>	11:01	–	<u>0.0097</u>
	29:02	<u>0.0186</u>	–
<i>HLA-C</i>	03:03	<u>0.0360</u>	–
<i>HLA-DQA1</i>	05:01	0.0511	–
<i>HLA-DQB1</i>	03:01	<u>0.0218</u>	–
	03:02	0.2657	–

Significant nominal *P*-values ($P < 0.05$) are underlined.

– not performed

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3 -Enrichment analysis of rare *HLA* alleles among male infertility phenotypes.

Locus	<i>P</i> -value			
	All cases vs Controls	SHV cases vs Controls	AST cases vs Controls	OLI cases vs Controls
<i>HLA</i> ^a	<u>1.0443 × 10⁻⁵</u>	<u>8.0640 × 10⁻⁶</u>	<u>0.0003</u>	<u>0.0003</u>
<i>HLA-A</i>	<u>0.0179</u>	<u>0.0085</u>	0.0660	0.0570
<i>HLA-B</i>	<u>0.0220</u>	<u>0.0268</u>	<u>0.0418</u>	0.0997
<i>HLA-C</i>	1	1	1	1
<i>HLA-DPA1</i>	1	0.4729	0.3982	0.2917
<i>HLA-DPB1</i>	1	1	1	1
<i>HLA-DQB1</i>	0.6226	0.6041	0.3039	0.2042
<i>HLA-DRB1</i>	0.0814	0.0714	0.1904	0.1219

^aall *HLA* genes covered in this study except *HLA-DRB3*, *-DRB4* and *-DRB5*.Significant nominal *P*-values (*P* < 0.05) for Fisher's exact test are underlined.

Table 4 -Association analysis for *HLA-DRB3*, *-DRB4* and *-DRB5* copy number polymorphism.

Gene	Frequencies				
	Controls	All cases	SHV cases	AST cases	OLI cases
<i>HLA-DRB3</i>	0.375	0.472	0.500	0.511	0.625
<i>HLA-DRB4</i>	0.412	0.310	0.295	0.289	0.214
<i>HLA-DRB5</i>	0.096	0.099	0.098	0.078	0.071
NULL ^a	0.118	0.120	0.107	0.122	0.089

Gene	P-value				
	All cases vs Controls	SHV cases vs Controls	AST cases vs Controls	OLI cases vs Controls	
Single locus	0.3145	0.1835	0.1874	<u>0.0151</u>	
<i>HLA-DRB3</i>	0.1152	<u>0.0454</u>	0.0545	<u>0.0023</u>	
Multiple locus	<i>HLA-DRB4</i>	0.0815	0.0525	0.0671	<u>0.0123</u>
<i>HLA-DRB5</i>	1.0000	1.0000	0.8118	0.7817	

^aThe NULL designation corresponds to chromosomes lacking any copy of *HLA-DRB3*, *-DRB4* or *-DRB5*.

Significant nominal *P*-values (*P* < 0.05) for Fisher's exact test or χ^2 test are underlined.